Fox Run Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Fox Run Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19,247	Closed	-$92.2K	–	1261
2024 Q4	$92.2K	Sell	19,247 -14,199	-42%	-$68.2K	0.02%	812
2024 Q3	$157K	Buy	+33,446	New	+$179K	0.03%	698
2023 Q3	–	Sell	-21,890	Closed	-$144K	–	1015
2023 Q2	$144K	Buy	+21,890	New	+$140K	0.04%	617
2018 Q3	–	Sell	-28,611	Closed	-$545K	–	837
2018 Q2	$545K	Buy	28,611 +5,516	+24%	+$92.2K	0.17%	205
2018 Q1	$389K	Buy	+23,095	New	+$387K	0.09%	401
2017 Q4	–	Sell	-38,900	Closed	-$696K	–	905
2017 Q3	$696K	Buy	+38,900	New	+$651K	0.2%	167
2017 Q2	–	Sell	-19,000	Closed	-$266K	–	856
2017 Q1	$266K	Buy	+19,000	New	+$271K	0.11%	406

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Fox Run Management's VNDA Position: Q1 2025 in Review

Fox Run Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2025, closing a stake of 19,247 shares — an estimated $92.2K sold.

Fox Run Management first reported a position in VNDA in Q1 2017 and held it in 7 quarters. The position peaked at $696K in Q3 2017. 146 funds tracked by Wall St. Rank hold VNDA as of Q1 2025.

Fox Run Management reported no remaining Vanda Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Fox Run Management sold 19,247 Vanda Pharmaceuticals shares in Q1 2025, an estimated $92.2K.
Fox Run Management first reported a position in Vanda Pharmaceuticals in Q1 2017 and held it in 7 quarters.
Fox Run Management's Vanda Pharmaceuticals position peaked at $696K in Q3 2017.
146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2025.

Based on Fox Run Management's 13F filing for Q1 2025, filed 13 May 2025.